Affiliate disclosure: RENVA may earn commissions from some provider links on this page. Affiliate status has zero weight in our scoring or editorial conclusions. Full disclosure →
By Darrin LaVelle, Founder of RENVA Health · July 31, 2026
JULY 31, 2026 — An FDA advisory committee voted this week to recommend that six popular but unapproved peptides — including BPC-157 and TB-500 — be added to the list of substances compounding pharmacies are legally permitted to prepare. The vote is non-binding, and none of the peptides are legal to compound today.
Over two days, July 23–24, the FDA's Pharmacy Compounding Advisory Committee (PCAC) reviewed seven peptides being considered for the Section 503A Bulk Drug Substances List. Six were recommended in narrow votes that overrode objections from the FDA's own career scientists:
One peptide, emideltide (also known as DSIP), was rejected in a 6–7 vote.
What happened: FDA staff scientists had recommended against including any of the seven, citing short, small, and underpowered studies — including just five human trials of BPC-157 — that they said were insufficient to establish safety or effectiveness across the proposed indications, which spanned ulcerative colitis, wound healing, obesity, osteoporosis, and opioid withdrawal. The committee, whose roster was reconstituted ahead of the meeting with increased representation from clinicians and businesses involved in prescribing, producing, or promoting peptides, voted against that recommendation.
Why it matters:none of the six recommended peptides are legal for compounding pharmacies to prepare today, and won't be for some time. The PCAC's vote is advisory only — the FDA must still decide whether to adopt the recommendation, and a favorable decision would trigger formal rulemaking, including a public comment period. Legal analysts estimate the full process typically takes 12 to 24 months from a favorable committee vote to any substance actually becoming legally compoundable.
The vote follows an earlier step in April 2026, when the FDA removed BPC-157 and TB-500 from its "Category 2" list of substances flagged for significant safety concerns, clearing the procedural path for this review.
What it means for consumers:in the meantime, the FDA retains its existing authority to take enforcement action against pharmacies compounding these substances. Patients and providers currently using or offering these peptides should understand that this week's vote changed nothing about their legal status today, regardless of how it's characterized in marketing materials.
RENVA will update its Longevity provider pages and related coverage as the FDA's formal rulemaking process develops.
RENVA Health is an independent telehealth comparison site. RENVA is not a healthcare provider and this article does not constitute medical advice. See RENVA's full Affiliate Disclosure.
Media inquiries: hello@renva.health
Medical disclaimer: RENVA is not a healthcare provider. This article is informational only. It does not constitute medical advice. Full disclaimer →
Affiliate disclosure: Affiliate relationships do not influence editorial conclusions. Full disclosure →